compounded semaglutide fda warning november 2025 Hims and Hers warns investors about potential liability for FDA-regulated prescription drug ads – Partnership for Safe Medicines Compounded "semaglutide" is not FDA-approved

(Survey conducted by Pendulum.) (*These statements have not been evaluated by the Food and Drug Administration

How does Retatrutide compare with current weight loss treatments

FDA approval is projected for 2027 at the earliest

31, 2027, with

"Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." Press release

5 Ingredion's VITESSENCE pea protein isolates and concentrates deliver protein in clean label formats that support satiety without compromising texture or taste critical factors for creating high-protein food and beverages that consumers will enjoy